186 related articles for article (PubMed ID: 28556548)
21. [Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism].
Zhao J; Pan X; Xing Y; Lu M; Chen Y; Shi M
Zhonghua Yi Xue Za Zhi; 2015 Feb; 95(6):449-52. PubMed ID: 25916783
[TBL] [Abstract][Full Text] [Related]
22. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
[TBL] [Abstract][Full Text] [Related]
23. Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells.
Kuwana M; Medsger TA; Wright TM
J Immunol; 2000 Jun; 164(12):6138-46. PubMed ID: 10843663
[TBL] [Abstract][Full Text] [Related]
24. Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma.
Fava A; Cimbro R; Wigley FM; Liu QR; Rosen A; Boin F
Arthritis Res Ther; 2016 May; 18(1):99. PubMed ID: 27145754
[TBL] [Abstract][Full Text] [Related]
25. Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit.
Zhao Y; Jia Y; Li C; Shao R; Fang Y
Shock; 2019 Mar; 51(3):289-297. PubMed ID: 29702526
[TBL] [Abstract][Full Text] [Related]
26. PD-L2 is expressed on activated human T cells and regulates their function.
Messal N; Serriari NE; Pastor S; Nunès JA; Olive D
Mol Immunol; 2011 Sep; 48(15-16):2214-9. PubMed ID: 21752471
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of bovine programmed death-ligand 2.
Nishimori A; Konnai S; Ikebuchi R; Okagawa T; Nakajima C; Suzuki Y; Mingala CN; Murata S; Ohashi K
Microbiol Immunol; 2014 Jul; 58(7):388-97. PubMed ID: 24845976
[TBL] [Abstract][Full Text] [Related]
28. PD-L2 Regulates B-1 Cell Antibody Production against Phosphorylcholine through an IL-5-Dependent Mechanism.
McKay JT; Haro MA; Daly CA; Yammani RD; Pang B; Swords WE; Haas KM
J Immunol; 2017 Sep; 199(6):2020-2029. PubMed ID: 28768724
[TBL] [Abstract][Full Text] [Related]
29. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
Hu PQ; Fertig N; Medsger TA; Wright TM
Arthritis Rheum; 2003 May; 48(5):1363-73. PubMed ID: 12746909
[TBL] [Abstract][Full Text] [Related]
30. T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.
Kuwana M; Medsger TA; Wright TM
J Clin Invest; 1995 Jul; 96(1):586-96. PubMed ID: 7615831
[TBL] [Abstract][Full Text] [Related]
31. Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP): Potential Involvement of PD-1 Pathway in ITP Immunopathogenesis.
Birtas Atesoglu E; Tarkun P; Demirsoy ET; Geduk A; Mehtap O; Batman A; Kaya F; Cekmen MB; Gulbas Z; Hacıhanefioglu A
Clin Appl Thromb Hemost; 2016 Apr; 22(3):248-51. PubMed ID: 25510412
[TBL] [Abstract][Full Text] [Related]
32. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
Kuipers H; Muskens F; Willart M; Hijdra D; van Assema FB; Coyle AJ; Hoogsteden HC; Lambrecht BN
Eur J Immunol; 2006 Sep; 36(9):2472-82. PubMed ID: 16917960
[TBL] [Abstract][Full Text] [Related]
33. B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis.
Rizou C; Ioannidis JP; Panou-Pomonis E; Sakarellos-Daitsiotis M; Sakarellos C; Moutsopoulos HM; Vlachoyiannopoulos PG
Am J Respir Cell Mol Biol; 2000 Mar; 22(3):344-51. PubMed ID: 10696071
[TBL] [Abstract][Full Text] [Related]
34. [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer].
Nan J; Liang L; Li L; Xiaoqin S; Xing J; Yang C
Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):286-290. PubMed ID: 28675014
[TBL] [Abstract][Full Text] [Related]
35. Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis.
Hu PQ; Fertig N; Medsger TA; Wright TM
J Immunol; 2004 Aug; 173(4):2834-41. PubMed ID: 15295002
[TBL] [Abstract][Full Text] [Related]
36. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity.
Matsushita T; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
Rheumatology (Oxford); 2016 Feb; 55(2):263-7. PubMed ID: 26350483
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity.
Yoshizaki A; Komura K; Iwata Y; Ogawa F; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Clin Immunol; 2009 Mar; 29(2):180-9. PubMed ID: 18825489
[TBL] [Abstract][Full Text] [Related]
38. Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.
Hasegawa M; Fujimoto M; Matsushita T; Hamaguchi Y; Takehara K
Rheumatology (Oxford); 2013 Feb; 52(2):242-51. PubMed ID: 23024058
[TBL] [Abstract][Full Text] [Related]
39. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis.
Kuwana M; Kaburaki J; Mimori T; Kawakami Y; Tojo T
Arthritis Rheum; 2000 May; 43(5):1074-84. PubMed ID: 10817562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
